Novel Indications for Bruton’s Tyrosine Kinase Inhibitors, beyond Hematological Malignancies

Bruton’s tyrosine kinase (BTK) is a critical terminal enzyme in the B-cell antigen receptor (BCR) pathway. BTK activation has been implicated in the pathogenesis of certain B-cell malignancies. Targeting this pathway has emerged as a novel target in B-cell malignancies, of which ibrutinib is the fir...

Descripción completa

Detalles Bibliográficos
Autores principales: Campbell, Robert, Chong, Geoffrey, Hawkes, Eliza A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5920436/
https://www.ncbi.nlm.nih.gov/pubmed/29561760
http://dx.doi.org/10.3390/jcm7040062

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5920436/
https://www.ncbi.nlm.nih.gov/pubmed/29561760
http://dx.doi.org/10.3390/jcm7040062

Ejemplares similares